<?xml version="1.0" encoding="UTF-8"?>
<clinical_study rank="3174">
  <!-- This xml conforms to an XML Schema at:
    http://clinicaltrials.gov/ct2/html/images/info/public.xsd
 and an XML DTD at:
    http://clinicaltrials.gov/ct2/html/images/info/public.dtd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on June 04, 2014</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>http://clinicaltrials.gov/show/NCT01906801</url>
  </required_header>
  <id_info>
    <org_study_id>04-56-25</org_study_id>
    <nct_id>NCT01906801</nct_id>
  </id_info>
  <brief_title>Clinical Efficacy of Glucosamine Plus Diacerein Versus Mono-therapy of Glucosamine</brief_title>
  <sponsors>
    <lead_sponsor>
      <agency>Ramathibodi Hospital</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Ramathibodi Hospital</source>
  <oversight_info>
    <authority>Thailand: Ethical Committee</authority>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this study is to compare pain scores, WOMAC total and subscores, actual and
      change of joint space width and the rate of gastrointestinal side effects at 4, 8, 12, and
      24 weeks between dual-therapy of  diacerein and glucosamine versus a mono-therapy of
      glucosamine in OA patients
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date>July 2013</start_date>
  <completion_date type="Anticipated">April 2014</completion_date>
  <primary_completion_date type="Anticipated">April 2014</primary_completion_date>
  <phase>Phase 4</phase>
  <study_type>Interventional</study_type>
  <study_design>Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator, Outcomes Assessor), Primary Purpose: Treatment</study_design>
  <primary_outcome>
    <measure>pain visual analog scores</measure>
    <time_frame>24 weeks</time_frame>
    <safety_issue>No</safety_issue>
  </primary_outcome>
  <secondary_outcome>
    <measure>Western Ontario and McMaster Universities Osteoarthritis (WOMAC) scores</measure>
    <time_frame>24 weeks</time_frame>
    <safety_issue>No</safety_issue>
  </secondary_outcome>
  <secondary_outcome>
    <measure>actual and change of joint space width</measure>
    <time_frame>24 weeks</time_frame>
    <safety_issue>No</safety_issue>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Rate of gastrointestinal side effects</measure>
    <time_frame>24 weeks</time_frame>
    <safety_issue>Yes</safety_issue>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">148</enrollment>
  <condition>Osteoarthritis</condition>
  <condition>Glucosamine</condition>
  <condition>Diacerein</condition>
  <arm_group>
    <arm_group_label>Glucosamine sulfate &amp; Diacerein</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Glucosamine sulfate (sachet) 1500 mg and Diacerein 50 mg tablet by mouth once daily for 24 weeks</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Glucosamine sulfate &amp; Placebo</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Glucosamine sulfate 1500 mg and Placebo (for Diacerein) 50 mg by mouth once daily for 24 weeks</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Glucosamine sulfate</intervention_name>
    <arm_group_label>Glucosamine sulfate &amp; Diacerein</arm_group_label>
    <arm_group_label>Glucosamine sulfate &amp; Placebo</arm_group_label>
    <other_name>Viatril-S</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Diacerein</intervention_name>
    <arm_group_label>Glucosamine sulfate &amp; Diacerein</arm_group_label>
    <other_name>Artrodar</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Placebo (for Diacerein)</intervention_name>
    <description>Sugar pill manufactured to mimic Diacerein 50 mg tablet</description>
    <arm_group_label>Glucosamine sulfate &amp; Placebo</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Adult patients age 50 years or older who have been diagnosed as primary or secondary
        osteoarthritis of the knee base on clinical criteria  of American College of Rheumatology

        Inclusion Criteria:

          -  Clinical diagnosis of primary osteoarthritis

          -  Mild deformity Clinical (having no varus or valgus deformity, no crepitus) ? Physical
             examination grade 0 assessed by stress test Radiographic assessment
             (Kellgrane-lawrance type II-III), a minimum baseline medial tibiofemoral JSW of _2
             mm.

          -  Willing to participate and provide written informed consent

        Exclusion Criteria:

          -  Non-secondary osteoarthritis Rheumatoid arthritis,  inflammatory arthritis (e.g. SLE,
             Gout),  post traumatic osteoarthritis, those who received intra-articular treatment
             of the signal joint with any product (corticosteroids in the previous 2 months, or
             glycosaminoglycans/hyaluronic acid in the previous 6 months) or had undergone joint
             lavage andarthroscopic procedures in the previous 6 months.

          -  No contraindication of using diacerein and glucosamine

          -  Non-current or ex-users of oral SYSADOA (e.g., glucosamine sulphate, chondroitin
             sulphate, diacerein, piascledine), anti-depressants, tranquillisers, antacids or
             antibiotics known hypersensitivity to diacerein, to similar compounds, to the
             excipients or to paracetamol
      </textblock>
    </criteria>
    <gender>Both</gender>
    <minimum_age>50 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Patarawan Woratanarat, MD, Ph.D</last_name>
    <role>Study Director</role>
    <affiliation>Department of Orthopaedics, Faculty of Medicine Ramathibodi Hospital, Bangkok, Mahidol University, Thailand.</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Ammarin Thakkinstian, Ph.D</last_name>
    <role>Study Chair</role>
    <affiliation>Section for Clinical Epidemiology and Biostatistics, Faculty of Medicine Ramathibodi Hospital, Bangkok, Thailand</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Jatupon Kongtharvonskul, MD</last_name>
    <phone>+66896675440</phone>
    <email>Jatupon_kong@hotmail.com</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Ammarin Thakkinstian, Ph.D</last_name>
    <email>ammarin.tak@mahidol.ac.th</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>Department of Orthopaedics, Faculty of Medicine Ramathibodi Hospital, Bangkok, Mahidol University</name>
      <address>
        <city>Bangkok</city>
        <zip>10400</zip>
        <country>Thailand</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Siwadol Wongsak, MD</last_name>
      <phone>+66819003177</phone>
      <email>Siwadolra@hotmail.com</email>
    </contact>
    <contact_backup>
      <last_name>Sudasiri Sriwiang</last_name>
      <phone>+6622012684</phone>
      <email>sudasiri.sri@mahidol.ac.th</email>
    </contact_backup>
  </location>
  <location_countries>
    <country>Thailand</country>
  </location_countries>
  <verification_date>July 2013</verification_date>
  <lastchanged_date>July 23, 2013</lastchanged_date>
  <firstreceived_date>July 20, 2013</firstreceived_date>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Ramathibodi Hospital</investigator_affiliation>
    <investigator_full_name>Jatupon Kongtharvonskul</investigator_full_name>
    <investigator_title>Section for Clinical Epidemiology and Biostatistics, Faculty of Medicine Ramathibodi Hospital, Bangkok, Thailand</investigator_title>
  </responsible_party>
  <keyword>Osteoarthritis</keyword>
  <keyword>Glucosamine sulfate</keyword>
  <keyword>Diacerein</keyword>
  <keyword>Randomized controlled trial</keyword>
  <is_fda_regulated>No</is_fda_regulated>
  <has_expanded_access>No</has_expanded_access>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm  -->
    <mesh_term>Osteoarthritis</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm  -->
    <mesh_term>Diacetylrhein</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                -->
</clinical_study>
